Clinical Trials Logo

Deleterious PALB2 Gene Mutation clinical trials

View clinical trials related to Deleterious PALB2 Gene Mutation.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04584255 Recruiting - Breast Cancer Clinical Trials

Niraparib + Dostarlimab In BRCA Mutated Breast Cancer

Start date: December 18, 2020
Phase: Phase 2
Study type: Interventional

This research study involves pre-operative therapy that is specifically targeted for breast cancer in individuals with BRCA and PALB2 mutations. The names of the study drugs involved in this study are: - Niraparib (Zejula) - Dostarlimab